--- title: "Jingtai Technology VS RXRX" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/35837188.md" description: "$XTALPI(02228.HK) $Recursion Pharmaceuticals(RXRX.US) Company fundamental indicatorsRecursion Pharmaceuticals (RXRX.US) XtalPi (2228.HK) Established20132015, founded by three MIT PhDs in PhysicsListed onApril 16, 2021, NASDAQJune 13, 2024..." datetime: "2025-10-31T04:29:52.000Z" locales: - [en](https://longbridge.com/en/topics/35837188.md) - [zh-CN](https://longbridge.com/zh-CN/topics/35837188.md) - [zh-HK](https://longbridge.com/zh-HK/topics/35837188.md) author: "[老板的老板 AI Exec](https://longbridge.com/en/profiles/123.md)" --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/topics/35837188.md) | [繁體中文](https://longbridge.com/zh-HK/topics/35837188.md) # Jingtai Technology VS RXRX $XTALPI(02228.HK) $Recursion Pharmaceuticals(RXRX.US) Company Fundamentals Metric Recursion Pharmaceuticals (RXRX.US) XtalPi (2228.HK) Founded 2013 2015, co-founded by three MIT PhDs in Physics IPO Date/Location April 16, 2021, Nasdaq June 13, 2024, Hong Kong Main Board (First Chapter 18C Specialized Tech Listing) HQ Salt Lake City, Utah, USA Shenzhen, China (primary) & Boston, USA (R&D lab) Employees ~800 (end-2024) ※20% layoff in mid-2025 (~640 remaining) 700+ (mostly scientists/technicians) Founding Team Co-founders: Chris Gibson (Bioengineering PhD), Dean Li (MD), Blake Borgeson (CS PhD). Interdisciplinary R&D focus integrating biology with data science. Co-founders: Shuhao Wen, Jian Ma, Lipeng Lai (all Physics PhDs from MIT). Applied quantum physics + AI to drug discovery. Vision & Mission **Decoding Biology**: Industrial-scale automated experiments + AI to map bio/chemical space for faster drug discovery. Aims to disrupt traditional pharma paradigms. **AI-Powered Research**: "AI + Quantum Physics + Robotics" platform. Philosophy: "Do hard but right things" - data-driven acceleration for drug/material R&D with full-process smart solutions. \*\*Analysis:\*\* Recursion is a leading US AI drug discovery firm rooted in academia (founded 2013, Nasdaq 2021). Its Salt Lake City-based team combines medical/engineering expertise to "decode biology." XtalPi represents China's tech-driven biotech, founded by MIT PhDs in 2015 and listed as Hong Kong's first Chapter 18C specialized tech firm in 2024. With dual HQs in Shenzhen/Boston, XtalPi applies physics algorithms + AI to medicine. Both have similar team sizes (~800 for Recursion, 700+ for XtalPi) and share the "TechBio" pioneer ethos - using AI/automation to transform drug R&D, albeit with different approaches. ## Technology & Core Capabilities - **Recursion:** Its proprietary "Recursion OS" integrates biology, chemistry, automation, and data science. Features automated cell experiments generating massive phenotypic data via high-throughput imaging, analyzed by deep learning to uncover drug mechanisms. Key innovation: Combining large-scale phenotypic databases with ML to map "biological relationship networks," revealing hidden gene-phenotype-compound links. Claims to have digitized physical experiments into searchable bio/chemical relationships (trillions of data points). End-to-end platform spans genomics-to-clinical stages, with AI guiding target discovery, lead optimization, and trial design. Expanded capabilities via acquisitions (e.g., 2023 purchases of Cyclica and Valence for AI chemistry/generative AI). Holds ~58 global patents covering compound discovery orchestration, ML analysis of perturbation data, etc. Core moat: Unique biological data + interdisciplinary AI platform enabling integrated optimization. Demonstrates hypothesis-free phenotypic screening to clinical candidate generation. - **XtalPi:** Integrates quantum physics, AI algorithms, cloud computing, and robotic automation. Initially renowned for small-molecule crystal prediction (100% accuracy in Pfizer's 2016 challenge vs. industry's 86-93%). Expanded to drug design (small/large molecules) and solid-state research, combining algorithmic prediction with robotic lab validation. Developed autonomous lab tools: XmartChem (synthesis robots), XtalComplete (crystallization), PatSight (IP mining), XMolGen (molecular design). "AI+Robotics" platform automates compound synthesis, crystal forms, and bio-experiments. Currently holds 120+ patents, 27 active drug discovery projects, and 4 R&D centers (\>10,000 sqm labs). Full-chain capabilities: computational design → automated synthesis → characterization testing, applicable beyond pharma to materials science. Key strength: Precision algorithms (quantum chem, generative AI) + rapid robotic validation for faster iterations. Leads in crystal screening/molecular design accuracy/efficiency while commercializing modular platform tools. **Comparison:** Both emphasize AI+automation but differ in focus. Recursion starts with phenotypic data to build "biological maps" and target discovery, recently adding chemistry via M&A. XtalPi excels in physics-based computational precision, expanding horizontally across drug design with robotic validation. XtalPi's 120+ patents (vs. Recursion's ~58) reflect aggressive IP strategy. Recursion's moat: Proprietary data + AI integration; XtalPi's: Algorithm accuracy + hardware scalability for broad industry 赋能。 ## Business Models & Clients - **Recursion:** "Internal pipeline + strategic partnerships." Focuses on proprietary drug development (novel targets/mechanisms), supplemented by big pharma collaborations. Flagship 2021 deal with Roche/Genentech: $150M upfront for up to 40 programs ($1.2B potential). Later partnerships with Sanofi, Bayer, etc. Sanofi collaboration (2025) advanced 4/15 projects to candidate optimization ($7M milestone; $5.2B total potential). Typically grants partners global rights for milestone/royalty shares. Not a CRO - revenue depends on partnership progress. Also raised strategic investments (e.g., NVIDIA's $50M). No product revenue yet. - **XtalPi:** Hybrid "platform services + co-development." As an AI CRO/CRDMO, serves 16/20 top pharma (Pfizer, J&J, Merck, etc.) and Asian biotechs with customized solutions (e.g., crystal screening, lead optimization). Accelerated Pfizer's Paxlovid crystal form confirmation (6 weeks). Recent high-value co-development deals: Lilly (2023, up to $250M upfront), DoveTree (2025, $599M potential, $51M received). Revenue mix: service fees + milestone shares. Broader client base than Recursion, resembling an "AI-powered outsourcing platform." Also explores non-pharma applications (e.g., energy materials with CAS). **Comparison:** Recursion prioritizes internal pipelines (high-risk/high-reward) with selective mega-partnerships. XtalPi balances scalable services with shared-value co-development, ensuring steadier cash flow. Recursion's deals are fewer but larger (Roche/Sanofi); XtalPi has diverse projects, now securing Lilly/DoveTree-scale contracts. Long-term: Recursion resembles an "AI biopharma," XtalPi an "AI-enabled R&D ecosystem." ## Pipeline Maturity - **Recursion:** Clinical-stage with focus on oncology/rare diseases. Previously 11 candidates, now streamlined to 6 core programs (4 oncology, 2 rare) after 2024-2025 terminations. Key assets: REC-4881 (Phase II MEK inhibitor for FAP), REC-3964 (Phase I C. difficile toxin). Using AI for clinical trial design. No late-stage or commercial products yet. - **XtalPi:** 27 discovery/preclinical projects, mostly partner-driven. No proprietary clinical assets. Assisted partners like Taiwan's PharmaEngine in clinical-stage candidates. DoveTree collaboration includes preclinical molecules. Earlier-stage than Recursion but demonstrates "drug-generating" capability via partners. **Comparison:** Recursion is clinically advanced (multiple Phase I/II) but faces validation risks. XtalPi excels at "0-to-1" discovery, relying on partners for development. Recursion may see binary value inflection; XtalPi's risk/reward is distributed across multiple projects. ## Financials - **Recursion:** Heavy R&D spend ($128.6M Q2 2025, +74% YoY) with modest revenue ($19.2M Q2 2024, +33%). 2024 net loss: $464M; Q2 2025 loss: $171.9M. $533.8M cash (Jun-2025), projected runway to 2027 post-layoffs. Revenue/cost mismatch but claims 100x efficiency gains in early-stage costs. - **XtalPi:** Rapid revenue growth (RMB517M H1 2025, +404%), turning profitable (RMB141M adjusted net). Strong cash from IPO ($115M net) + Tencent/Sequoia backing. Higher capital efficiency via monetizable services. **Comparison:** Recursion burns cash awaiting pipeline success; XtalPi shows scalable monetization. Recursion's $2.5B valuation reflects platform potential; XtalPi's $6.2B values proven growth. ## Valuation & Market - **Recursion:** $2.5B market cap (30x P/S). Volatile: 52wk $3.79-$12.36. ARK Invest held 7%. Tech investors bet on long-term AI-bio story; pharma analysts await clinical proof. - **XtalPi:** $6.2B (60x P/S). Hong Kong's AI pharma leader, up 20% past year. Tencent-backed. High growth premium but needs sustained execution. **Comparison:** Recursion priced for binary clinical outcomes; XtalPi for execution visibility. Different investor bases (US tech/pharma vs. HK growth). ## Strategic Positioning - **Recursion:** "AI biopharma" pioneer with "Recursion OS" moat (data + automation + IP). NIH/DoD/NVIDIA endorsements. Challenges: clinical validation, cash burn. - **XtalPi:** "AI lab" provider with quantum physics + robotics edge. Serves broad industries. First-mover in China's policy-backed market. Challenges: platform defensibility vs. traditional CROs. **Investment Takeaway:** Recursion offers high-risk/high-reward bets; XtalPi provides growth with less binary risk. Both represent TechBio's promise - choose based on risk appetite. ### Related Stocks - [Recursion Pharmaceuticals, Inc. (RXRX.US)](https://longbridge.com/en/quote/RXRX.US.md) - [Pfizer Inc. (PFE.US)](https://longbridge.com/en/quote/PFE.US.md) - [XTALPI (02228.HK)](https://longbridge.com/en/quote/02228.HK.md) ## Comments (16) - **做自己 · 2026-01-13T03:54:12.000Z**: Mark learning - **大大王_水泊 · 2025-11-03T01:10:02.000Z**: one JD, one Taobao - **泰山长红 · 2025-10-31T13:55:38.000Z**: Consider after next week's earnings report, currently there is a possibility of breaking the support level - **老板的老板 AI Exec** (2025-10-31T13:57:08.000Z): Buy slowly, take time, it takes time to come out - **韭菜想赚钱 · 2025-10-31T05:30:21.000Z**: Thank you for sharing, boss. - **bojackwomo · 2025-10-31T05:17:51.000Z**: Can the boss's prompt be sent? - **老板的老板 AI Exec** (2025-10-31T05:19:42.000Z): Nothing special. Just using its deepresearch - **陆家嘴老毛桃 · 2025-10-31T05:14:02.000Z**: A research report has brought out all the shareholders of Longbridge RXRX - **椰丝不卷 · 2025-10-31T05:09:22.000Z · 👍 1**: Very detailed analysis 👍, thanks for the hard work 🙏. Another characteristic: RXRX management keeps selling shares, while XtalPi management keeps issuing more shares 😂 - **老板的老板 AI Exec** (2025-10-31T05:14:24.000Z): XtalPi's additional share issuance is actually a good thing. Large institutions take the new shares, and the company gets cash reserves to expand its ecosystem. This is a win-win situation and reduces - **龙行者 · 2025-10-31T04:49:46.000Z**: Boss, have you been following KVUE? How is this stock? - **Awei SHSF · 2025-10-31T04:48:14.000Z**: Learn - **就是要赚钱 · 2025-10-31T04:46:00.000Z**: Thank you, boss - **陆家嘴老毛桃 · 2025-10-31T04:42:17.000Z**: The boss's analysis is spot on, I can safely increase my position - **阿二每天都要开心呀 · 2025-10-31T04:35:50.000Z**: Massage massage - **大鹅来了 · 2025-10-31T04:35:35.000Z**: Cathie Wood's holdings seem to be